Program
romiplostim
Also written as “Romiplostim”, “AMG 531” and “GNR-069”.
Its studies are mostly in Purpura, Thrombocytopenic, Idiopathic · Anemia, Aplastic · Myelodysplastic Syndromes · Carcinoma, Non-Small-Cell Lung · Purpura, Thrombocytopenic, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Amgen | 252 open or running | phase 4since May 21, 2009 | Jan 27, 2005 | Sep 14, 2029phase 3 · NCT07700238 |
| Kyowa Kirin | 80 open or running | phase 3since Feb 22, 2007 | Mar 20, 2006 | none ahead |
| AO GENERIUM | 20 open or running | phase 3since Jan 21, 2022 | Jan 21, 2022 | none ahead |
| Geropharm | 21 open or running | phase 3since Jul 4, 2024 | Dec 7, 2022 | Mar 31, 2028phase 3 · NCT06497036 |
| Qilu Pharmaceutical | 11 open or running | phase 3since Dec 23, 2025 | Dec 23, 2025 | Oct 2029phase 3 · NCT07345000 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 23 studies since Jan 27, 2005.
- May 9, 2016Phase 3 study in Anemia, AplasticKyowa Kirin · NCT02773290 · 46 enrolled · Japan, Korea, Republic of
- Aug 11, 2016Phase 3 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868099 · 203 enrolled · China
- Aug 11, 2016Phase 2 study in Purpura, Thrombocytopenic, IdiopathicKyowa Kirin · NCT02868060 · 16 enrolled · China
- Oct 12, 20172 phase 3 studiesAmgen · NCT03362177, NCT03343847
- Apr 24, 2019Phase 3 study in Carcinoma, Non-Small-Cell LungAmgen · NCT03937154 · 145 enrolled · United States, Argentina, Brazil and more
- May 9, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT03957694 · 17 enrolled · Japan
- Sep 18, 2019Phase 3 study in Anemia, AplasticKyowa Kirin · NCT04095936 · 24 enrolled · Japan
- Jan 21, 2022AO GENERIUM's first study: phase 3 study in Purpura, Thrombocytopenic, IdiopathicNew to AO GENERIUMAO GENERIUM · NCT05220878 · 160 enrolled · Russian Federation
- Apr 5, 2022Phase 2 study in Anemia, AplasticAmgen · NCT05323617
- Aug 3, 2022Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAO GENERIUM · NCT05492409 · 160 enrolled · Russian Federation
- Dec 7, 2022Geropharm's first study: phase 1 study in PharmacodynamicsNew to GeropharmGeropharm · NCT05652595 · 56 enrolled · Russian Federation
- Jul 4, 2024Phase 3 study in Drug EffectGeropharm · NCT06497036 · 160 enrolled · Russian Federation
- Dec 23, 2025Qilu Pharmaceutical's first study: phase 3 study in Treatment-naïve Severe Aplastic AnemiaNew to Qilu PharmaceuticalQilu Pharmaceutical · NCT07345000 · 210 planned
- Jul 7, 2026Phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238 · 126 planned · United States
Ahead
- Mar 31, 2028Primary completion: phase 3 study in Drug EffectGeropharm · NCT06497036
- Sep 14, 2029Primary completion: phase 3 study in Purpura, Thrombocytopenic, IdiopathicAmgen · NCT07700238
- Oct 2029Primary completion: phase 3 study in Treatment-naïve Severe Aplastic AnemiaQilu Pharmaceutical · NCT07345000
TargetBeta
“Thrombopoietin receptor agonist”ChEMBL 37, by rule
Other programs on MPL
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| eltrombopagrule | GlaxoSmithKline | phase 4 | 49 |
| avatrombopagrule | Eisai | phase 4 | 25 |
| hetrombopag olaminerule | Jiangsu HengRui Medicine | phase 3 | 15 |
Studies
All 38 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07700238Purpura, Thrombocytopenic, Idiopathic · United States | 3 | Recruiting | Amgen | Sep 14, 2029 | 126 |
| NCT07345000Treatment-naïve Severe Aplastic Anemia | 3 | Not yet recruiting | Qilu Pharmaceutical | Oct 2029 | 210 |
| NCT06497036Drug Effect · Russian Federation | 3 | Active, not recruiting | Geropharm | Mar 31, 2028 | 160 |
| NCT05652595Pharmacodynamics · Russian Federation | 1 | UNKNOWN | Geropharm | Jun 30, 2024 | 56 |
| NCT05492409Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | AO GENERIUM | Apr 3, 2024 | 160 |
| NCT05323617Anemia, Aplastic | 2 | Withdrawn | Amgen | Feb 25, 2025 | 0 |
| NCT05220878Purpura, Thrombocytopenic, Idiopathic · Russian Federation | 3 | Completed | AO GENERIUM | Aug 22, 2023 | 160 |
| NCT04095936Anemia, Aplastic · Japan | 3 | Completed | Kyowa Kirin | Oct 7, 2021 | 24 |
| NCT03957694Anemia, Aplastic · Japan | 3 | Completed | Kyowa Kirin | Nov 5, 2020 | 17 |
| NCT03937154Carcinoma, Non-Small-Cell Lung · United States, Argentina, Brazil and more | 3 | Active, not recruiting | Amgen | Mar 10, 2026 | 145 |
| NCT03362177Gastrointestinal Neoplasms · United States, Argentina, Austria and more | 3 | Completed | Amgen | Jan 25, 2024 | 165 |
| NCT03343847Chemotherapy-induced Thrombocytopenia | 3 | Withdrawn | Amgen | Jul 17, 2021 | 0 |
| NCT02868099Purpura, Thrombocytopenic, Idiopathic · China | 3 | Completed | Kyowa Kirin | Feb 2017 | 203 |
| NCT02868060Purpura, Thrombocytopenic, Idiopathic · China | 2 | Completed | Kyowa Kirin | Aug 2017 | 16 |
| NCT02773290Anemia, Aplastic · Japan, Korea, Republic of | 3 | Completed | Kyowa Kirin | Nov 14, 2017 | 46 |
| NCT02279173Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Belgium and more | 3 | Completed | Amgen | Aug 30, 2018 | 203 |
| NCT02094417Anemia, Aplastic · Korea, Republic of | 2 | Completed | Kyowa Kirin | Apr 24, 2017 | 35 |
| NCT01444417Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada | 3 | Completed | Amgen | Feb 2015 | 62 |
| NCT01143038Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Czechia and more | 2 | Completed | Amgen | Sep 20, 2013 | 75 |
| NCT01071954Purpura, Thrombocytopenic, Idiopathic · United States, Australia, Canada and more | 3 | Completed | Amgen | Jan 12, 2017 | 66 |
| NCT00907478Thrombocytopenia | 4 | Completed | Amgen | Jan 9, 2014 | 169 |
| NCT00614523Myelodysplastic Syndromes | 2 | Completed | Amgen | Mar 31, 2011 | 250 |
| NCT00515203Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Amgen | Mar 2009 | 22 |
| NCT00508820Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Amgen | Jan 1, 2011 | 407 |
| NCT00472290Myelodysplastic Syndromes | – | Completed | Amgen | Jul 18, 2011 | 72 |
| NCT00440037Purpura, Thrombocytopenic · Japan | 3 | Completed | Kyowa Kirin | Jul 2011 | 44 |
| NCT00418665Myelodysplastic Syndromes | 2 | Completed | Amgen | Mar 2009 | 39 |
| NCT00415532Purpura, Thrombocytopenic, Idiopathic | 3 | Completed | Amgen | Nov 7, 2008 | 234 |
| NCT00413283Lung Neoplasms · United States, Austria, Canada and more | 2 | Completed | Amgen | Dec 2008 | 63 |
| NCT00321711Myelodysplastic Syndromes | 2 | Completed | Amgen | Oct 19, 2009 | 69 |
| NCT00305435Purpura, Thrombocytopenic | 2 | Completed | Kyowa Kirin | Nov 2006 | 12 |
| NCT00303472Thrombocytopenia | 2 | Completed | Amgen | May 2008 | 72 |
| NCT00283439Hodgkin Disease | 2 | Completed | Amgen | May 2008 | 39 |
| NCT00117143Purpura, Thrombocytopenic | 2 | Completed | Amgen | Jul 19, 2004 | 16 |
| NCT00116688Thrombocytopenia | 3 | Completed | Amgen | Jan 2010 | 313 |
| NCT00111475Purpura, Thrombocytopenic, Idiopathic | 2 | Completed | Amgen | Jun 17, 2004 | 45 |
| NCT00102336Thrombocytopenia | 3 | Completed | Amgen | Dec 1, 2006 | 62 |
| NCT00102323Thrombocytopenia | 3 | Completed | Amgen | Sep 1, 2006 | 63 |
How it is read
Names in the registry
- “Romiplostim”, 22 entries
- “AMG 531”, 6 entries
- “GNR-069”, 2 entries
- “Romiplostim N01”, 1 entry
- “GP404141”, 1 entry
Conditions, from the studies’ own filings
- Purpura, Thrombocytopenic, Idiopathic, 18 studies
- Anemia, Aplastic, 6 studies
- Myelodysplastic Syndromes, 4 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Purpura, Thrombocytopenic, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.